Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of LY3209590 in T2DM Treated With Basal Insulin
NCT03736785Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Feb 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in HbA1c at 32 weeks. Started Nov 2018; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03736785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736785.